Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GD iExo 003

Next Previous
Drug Profile

GD iExo 003

Alternative Names: GD-iExo-003; Induced pluripotent stem cell exosome - Guidon Pharmaceutics; Intravenous exosomes derived from human induced pluripotent stem cell - Guidon Pharmaceutics

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guidon Pharmaceutics
  • Class Exosome therapies
  • Mechanism of Action Exosome replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ischaemic stroke

Most Recent Events

  • 06 Feb 2025 Guidon Pharmaceutics plans a phase 0 trial for Vitiligo in China (Intralesional, Injection) in February 2025 (NCT06810869)
  • 27 May 2024 Phase-I clinical trials in Ischaemic stroke in China (IV) (NCT06138210)
  • 18 Nov 2023 Guidon Pharmaceutics and XuanWu Hospital Capital Medical University plan the phase I ExoCURE trial for Stroke (IV, Injection), in January 2024 (NCT06138210)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top